Literature DB >> 23512999

The impact of implementing The Bethesda System for reporting of thyroid FNA at an academic center.

Constantine Theoharis1, Adebowale J Adeniran, Sanziana Roman, Julie Ann Sosa, David Chhieng.   

Abstract

Recently, a six-tiered diagnostic risk classification system was created based on the recommendations of the National Cancer Institute (NCI) sponsored NCI Thyroid Needle Aspiration State of the Science Conference at Bethesda, MD in October 2007. The objective of the current study was to compare the frequency distribution of the various diagnostic categories to evaluate its diagnostic performance before and after implementation of The Bethesda System (TBS). A total of 5,897 thyroid Fine needle aspirations (FNAs) were reviewed; 3,207 were from 2008 after TBS implementation, and 2,690 were from 2007 immediately before TBS implementation. Follow-up consisted of reviewing corresponding histologic results. The rates of "Nondiagnostic" specimens and cases with a diagnosis of "Follicular Neoplasm" decreased from 13.1 to 11.1% and 8.6 to 5.5%, respectively, after implementation of TBS, while the rate of negative specimens increased from 68.2 to 73.8%. The other categories remained relatively stable. In addition, there also was a significant decrease in the use of noncommittal descriptive diagnoses. The diagnostic performance of thyroid FNA in identifying a neoplastic process as measured by area under the receiver operating characteristic curve increased from 0.88 to 0.89; the difference was statistically significant (P=0.03). Implementation of TBS showed a significant reduction of: nondiagnostic thyroid FNAs, of FNAs with a diagnosis of "Follicular Neoplasm," as well as cases with descriptive noncommittal diagnoses. TBS results in improved diagnostic performance and therefore more consistent and uniform reporting of thyroid FNA.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  Bethesda; fine needle aspiration; thyroid

Mesh:

Year:  2013        PMID: 23512999     DOI: 10.1002/dc.22970

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  6 in total

1.  The 5-tiered categorization system for reporting cytology is sufficient for management of patients with thyroid nodules compared to the 6-tiered Bethesda system.

Authors:  Jieun Koh; Hee Jung Moon; Eun-Kyung Kim; Jin Young Kwak; Jung Hyun Yoon
Journal:  Endocrine       Date:  2016-01-12       Impact factor: 3.633

2.  Incidental papillary thyroid carcinoma: diagnostic findings in a series of 287 carcinomas.

Authors:  Fabio Pagni; Marta Jaconi; Alberto Delitala; Mattia Garancini; Matteo Maternini; Francesca Bono; Alessandro Giani; Andrew Smith
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

3.  False-negative results with the Bethesda System of reporting thyroid cytopathology: predictors of malignancy in thyroid nodules classified as benign by cytopathologic evaluation.

Authors:  Bryan K Richmond; Rudy Judhan; Benny Chong; Adam Ubert; Zachary AbuRahma; William Mangano; Stephanie Thompson
Journal:  Am Surg       Date:  2014-08       Impact factor: 0.688

4.  Malignancy rates for Bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB).

Authors:  Leticia Mosca; Luiz Fernando Ferraz da Silva; Paulo Campos Carneiro; Danielle Azevedo Chacon; Vergilius Jose Furtado de Araujo-Neto; Vergilius Jose Furtado de Araujo-Filho; Claudio Roberto Cernea
Journal:  Clinics (Sao Paulo)       Date:  2018-05-28       Impact factor: 2.365

5.  Histopathological Review of Diagnostic Categories of the Bethesda System for Reporting Thyroid Cytopathology - An Institutional Experience of 5 Years.

Authors:  Paricha Upadhyaya; Sushil Dhakal; Purbesh Adhikari; Bindu Adhikari; Dibika Khadka; Surya R Niraula
Journal:  J Cytol       Date:  2019 Jan-Mar       Impact factor: 1.000

6.  Diagnostic value of fine-needle aspiration combined with ultrasound for thyroid cancer.

Authors:  Juan Li; Qian Wang; Liangliang Wang; Jing Wang; Dongxiao Wang; Zhaoqin Xin; Yilin Liu; Qinghua Zhao
Journal:  Oncol Lett       Date:  2019-07-05       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.